• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Perceived Level of Life Enjoyment and Risk of Developing Disabling Dementia: The Japan Public Health Center-Based Study
DISCUSSION: A higher level of life enjoyment was associated with a lower risk of disabling dementia, particularly in the low-medium mental stress group. This finding suggests the importance of having life enjoyment by managing mental stress for reducing risk of disabling dementia.PMID:37718836 | DOI:10.1093/geronb/gbad129
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Tomokazu Tajima Ai Ikeda Takeshi Tanigawa Hiroyasu Iso Kazumasa Yamagishi Takumi Matsumura Nobufumi Yasuda Manami Inoue Shoichiro Tsugane Norie Sawada Japan Public Health Center –Based Study Group Source Type: research

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news

Relationship Between Direct Oral Anticoagulant Doses and Clinical Outcomes in Elderly Patients With Non-Valvular Atrial Fibrillation 　- ANAFIE Registry Sub-Analysis
CONCLUSIONS: Inappropriate low DOAC doses (under- or off-label dose) were not associated with stroke/SEE or major bleeding but were associated with all-cause death.PMID:37482411 | DOI:10.1253/circj.CJ-23-0143
Source: Circulation Journal - July 23, 2023 Category: Cardiology Authors: Masaharu Akao Hiroshi Inoue Takeshi Yamashita Hirotsugu Atarashi Takanori Ikeda Yukihiro Koretsune Ken Okumura Shinya Suzuki Hiroyuki Tsutsui Kazunori Toyoda Atsushi Hirayama Masahiro Yasaka Takenori Yamaguchi Satoshi Teramukai Tetsuya Kimura Yoshiyuki Mo Source Type: research

Probabilistic graphical modelling using Bayesian networks for predicting clinical outcome after posterior decompression in patients with degenerative cervical myelopathy
CONCLUSIONS: The causal predictors of surgical outcome for DCM were sex, dementia and PreJOA score. Therefore, PGM may be a useful personalized medicine tool for predicting the outcome of patients with DCM.PMID:37435966 | DOI:10.1080/07853890.2023.2232999
Source: Annals of Medicine - July 12, 2023 Category: Internal Medicine Authors: Dong Ah Shin Sun-Ho Lee Sohee Oh Changwon Yoo Hee-Jin Yang Ikchan Jeon Sung Bae Park Source Type: research

Serum folate and risk of disabling dementia: a community-based nested case-control study
CONCLUSION: In this nested case-control study with a long follow-up, low serum folate levels were associated with an increased risk of disabling dementia among Japanese individuals.PMID:37314940 | DOI:10.1080/1028415X.2023.2218533
Source: Cancer Control - June 14, 2023 Category: Cancer & Oncology Authors: Rie Kishida Kazumasa Yamagishi Ai Ikeda Mina Hayama-Terada Yuji Shimizu Isao Muraki Mitsumasa Umesawa Hironori Imano Tomoko Sankai Takeo Okada Akihiko Kitamura Masahiko Kiyama Hiroyasu Iso CIRCS Investigators Source Type: research

Dietary diversity and risk of late-life disabling dementia in middle-aged and older adults
CONCLUSIONS: Our findings indicate that eating a variety of foods may prevent disabling dementia only among women. Thus, the habit of consuming a variety of food items has important public health implications for women.PMID:36863290 | DOI:10.1016/j.clnu.2023.02.002
Source: Cancer Control - March 2, 2023 Category: Cancer & Oncology Authors: Rei Otsuka Shu Zhang Hikaru Ihira Norie Sawada Manami Inoue Kazumasa Yamagishi Nobufumi Yasuda Shoichiro Tsugane Source Type: research

As some hail new antibody treatment for Alzheimer ’s, safety and benefit questions persist
In a packed San Francisco conference room with a celebratory atmosphere, upbeat company representatives and scientists yesterday presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp of being greenlit by the U.S. Food and Drug Administration (FDA). Yet other researchers warn of potential risks, including brain swelling and brain hemorrhages that were linked to the recently disclosed deaths of two trial participants wh...
Source: Science of Aging Knowledge Environment - December 1, 2022 Category: Geriatrics Source Type: research

Second death linked to potential antibody treatment for Alzheimer ’s disease
A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a massive brain hemorrhage that some researchers link to the drug. The clinical trial death, described in an unpublished case report Science has obtained, is the second thought to be associated with the antibody called lecanemab. The newly disclosed fatality intensifies questions about its safety and how widely lecanemab should be prescribed if ultimately approved by regulators. The woman, who received infusions of the antibody as part of the trial, s...
Source: ScienceNOW - November 28, 2022 Category: Science Source Type: news

Actual Telemedicine Needs of Japanese Patients with Neurological Disorders in the COVID-19 Pandemic
Conclusion We can contribute to the management of the COVID-19 pandemic and the medical economy by promoting telemedicine, especially for young patients with headaches or epilepsy.PMID:36418105 | DOI:10.2169/internalmedicine.9702-22
Source: Internal Medicine - November 23, 2022 Category: Internal Medicine Authors: Ryo Sasaki Taijun Yunoki Yumiko Nakano Yusuke Fukui Mami Takemoto Ryuta Morihara Koji Abe Toru Yamashita Source Type: research

Pages: 1  2  3  4  5